Sign In
Buy CYRX
CryoPort Earnings Calls
| Release date | May 04, 2026 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.230 |
| EPS Surprise | -15.00% |
| Revenue estimate | 44.863M |
| Revenue actual | 47.798M |
| Revenue Surprise | 6.54% |
| Release date | Mar 03, 2026 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.210 |
| EPS Surprise | -10.53% |
| Revenue estimate | 42.854M |
| Revenue actual | 45.45M |
| Revenue Surprise | 6.06% |
| Release date | Nov 04, 2025 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.180 |
| EPS Surprise | 21.74% |
| Revenue estimate | 42.924M |
| Revenue actual | 44.233M |
| Revenue Surprise | 3.05% |
| Release date | Aug 05, 2025 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.290 |
| EPS Surprise | -45.00% |
| Revenue estimate | 41.552M |
| Revenue actual | 45.454M |
| Revenue Surprise | 9.39% |
Last 4 Quarters for CryoPort
Below you can see how CYRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $6.74 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.290 |
| EPS surprise | -45.00% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $7.54 |
| Jul 31, 2025 | $7.33 |
| Aug 01, 2025 | $7.27 |
| Aug 04, 2025 | $7.16 |
| Aug 05, 2025 | $6.74 |
| Aug 06, 2025 | $8.75 |
| Aug 07, 2025 | $8.20 |
| Aug 08, 2025 | $7.56 |
| Aug 11, 2025 | $8.09 |
| 4 days before | -10.61% |
| 4 days after | 20.03% |
| On release day | 29.82% |
| Change in period | 7.29% |
| Release date | Nov 04, 2025 |
| Price on release | $9.22 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.180 |
| EPS surprise | 21.74% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $9.24 |
| Oct 30, 2025 | $9.00 |
| Oct 31, 2025 | $9.24 |
| Nov 03, 2025 | $9.04 |
| Nov 04, 2025 | $9.22 |
| Nov 05, 2025 | $8.53 |
| Nov 06, 2025 | $8.33 |
| Nov 07, 2025 | $8.38 |
| Nov 10, 2025 | $8.54 |
| 4 days before | -0.216% |
| 4 days after | -7.38% |
| On release day | -7.48% |
| Change in period | -7.58% |
| Release date | Mar 03, 2026 |
| Price on release | $8.49 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.210 |
| EPS surprise | -10.53% |
| Date | Price |
|---|---|
| Feb 25, 2026 | $8.48 |
| Feb 26, 2026 | $8.53 |
| Feb 27, 2026 | $8.42 |
| Mar 02, 2026 | $8.21 |
| Mar 03, 2026 | $8.49 |
| Mar 04, 2026 | $8.74 |
| Mar 05, 2026 | $8.36 |
| Mar 06, 2026 | $8.09 |
| Mar 09, 2026 | $8.09 |
| 4 days before | 0.118% |
| 4 days after | -4.71% |
| On release day | 2.94% |
| Change in period | -4.60% |
| Release date | May 04, 2026 |
| Price on release | $10.21 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.230 |
| EPS surprise | -15.00% |
| Date | Price |
|---|---|
| Apr 28, 2026 | $10.09 |
| Apr 29, 2026 | $9.80 |
| Apr 30, 2026 | $10.26 |
| May 01, 2026 | $10.35 |
| May 04, 2026 | $10.21 |
| May 05, 2026 | $12.19 |
| May 06, 2026 | $12.69 |
| May 07, 2026 | $12.76 |
| May 08, 2026 | $13.60 |
| 4 days before | 1.19% |
| 4 days after | 33.20% |
| On release day | 19.39% |
| Change in period | 34.79% |
CryoPort Earnings Call Transcript Summary of Q1 2026
Cryoport reported a strong start to FY2026 with revenue of $47.8M, up 16% year-over-year, driven by 26% growth in commercial cell and gene therapy support and 18% growth in clinical-trial-related revenue. The company supports a record 766 global clinical trials (91 in Phase III) and now supports 21 commercial therapies, with management noting up to 8 additional potential approvals in 2026. Life Sciences Services revenue rose 18% (BioStorage/BioServices +21%) and Life Sciences Products grew 15%, led by demand for MVE cryogenic systems and the new Fusion 800 series. Cryoport raised full-year 2026 revenue guidance to $192–$196M and expects to reach positive adjusted EBITDA in the second half of 2026, driven by revenue growth, facility ramps (Paris and Santa Ana), continued product demand, and operational efficiencies (including generative AI initiatives). IntegriCell shipped its first cryopreserved clinical trial patient materials from Houston and Belgium, marking initial commercialization progress for that offering. Management emphasized continued operational discipline, improving adjusted EBITDA (a $2.2M year-over-year improvement in Q1), and that new facilities will contribute more meaningfully in 2027.
